Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment‐resistant depression
A. P. Jesus-Nunes, Gustavo C. Leal, Fernanda S. Correia-Melo, Flávia Vieira, Rodrigo P Mello, A. T. Caliman-Fontes, Mariana V F Echegaray, Roberta F. Marback, Lívia N F Guerreiro-Costa, Breno Souza-Marques, Cassio Santos-Lima, Lucca S. Souza, Igor D. Bandeira, Flávio Kapczinski, Acioly L T Lacerda, Lucas C Quarantini
Human Psychopharmacology February 18, 2022 DOI: 10.1002/hup.2836 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Observational cohort Peer reviewed |
|---|---|
| Population | People with treatment-resistant depression |
| Interventions | Racemic ketamine Esketamine |
| Duration | 24 hours and 7 days after infusion |
| Topics | Depression Esketamine Ketamine |
| Citations | 39 |
| Key findings | Clinical predictors of depressive symptom remission and response were identified 24 hours and 7 days after racemic ketamine and esketamine infusions. |
Abstract
Major depressive disorder (MDD) is a leading cause of disability worldwide and most people do not achieve symptom remission. Treatment‐resistant depression (TRD) is characterized by the failure of at least one adequate trial of a major class of antidepressant, with adequate time and dosage. We aimed to identify clinical predictors of depressive symptom remission and response 24 h and 7 days after racemic ketamine and esketamine infusions.